Yes. HISTORY OF CANDIDA AURIS. Candida Auris was first described after it was isolated from the ear canal of a 70-year-old Japanese woman at the Tokyo Metropolitan Geriatric Hospital in Japan. It is one of the few species of the genus Candida which cause candidiasis in humans. It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. Infections have occurred primarily in patients who were already in the hospital for other reasons. However, C. auris is harder to identify from cultures than other, more common types of Candida. Critically ill patients admitted to the ICU are colonized by C. auris in an outbreak setting. However, many of these people had other serious illnesses that also increased their risk of death. People who have recently spent time in nursing homes and have lines and tubes that go into their body (such as breathing tubes, feeding tubes and central venous catheters), seem to be at highest risk for C. auris infection. Since the first reports in 2009, many isolates across five continents have been identified as agents of hospital-associated infections. Like other Candida infections, C. auris infections are usually diagnosed by culture of blood or other body fluids. The proportion of infections caused by each species varies by geographic region and by patient population.10 Although C. albicans is still the leading cause of candidemia in the United States, increasing proportions of cases in recent years have been attributed to non-albicans species that are often resistant to antifungal drugs.11-13 Altogether, non-C. albicans species cause approximately two-thirds of candidemia cases in the United States.3,11 In some locations, C. glabrata is the most common species. Some types of Candida are increasingly resistant to the first-line and second-line antifungal medications, such as fluconazole and the echinocandins (anidulafungin, caspofungin, and micafungin). CDC is providing guidance for clinicians and infection control personnel. INTRODUCTION. 16. Candida auris was first reported from Japan in 2009 from the external ear canal of a patient. It also has been isolated from respiratory and urine specimens, but it is unclear if it causes infections in the lung or bladder. Because of these factors, CDC is alerting U.S. healthcare facilities to be on the lookout for C. auris in their patients. More than 70% of these resistant isolates are the species C. glabrata or C. krusei.11,15 CDC’s surveillance data indicate that the proportion of Candida isolates that are resistant to fluconazole has remained fairly constant over the past 20 years.11,16,17 Echinocandin resistance, however, appears to be emerging, especially among C. glabrata isolates. C. auris can cause invasive candidiasis in which the bloodstream, the central nervous system, and internal organs are infected. Some strains are resistant to all three available classes of antifungals. Candida auris (C. auris) is an emerging multidrug-resistant type of Candida that presents a serious global health threat, including in the United States.14 It can cause severe infections and spreads easily in healthcare facilities. Candida auris is an emerging multidrug-resistant yeast that can cause invasive candidiasis and is associated with high mortality. The fungus causes invasive infections with a high death rate (about 57%) and causes mainly bloodstream, wound, and ear infections. Among all ages, candidemia rates are approximately twice as high in Black people as in non-Black people. Resistance to fluconazole, amphotericin B, caspofungin, micafungin and anidulafungin in C. auris were 91, 12, 12.1, 0.8 and 1.1%. We report finding 17 cases of C. auris infection that were originally misclassified but correctly identified 27.5 days later on average. Often, candidiasis is acquired in hospitals by patients with weakened immune systems. However, not all of them develop life-threatening … The germ, a fungus called Candida auris, preys on people with weakened immune systems, and it is quietly spreading across the globe. C. auris in the Middle-East Learn more about methods used for CDC’s candidemia surveillance through EIP. Overall, 70% were multidrug-resistant. In spite of the recent emergence of Candida auris, it has become a major drug resistant pathogen. Data like those are why the US Centers for Disease Control and Prevention (CDC) calls Candida a Please see the Recommendations for Laboratorians and Health Professionals. Identification of C. auris infections is often difficult, as it is commonly misidentified as other Candida species. It has caused outbreaks in healthcare settings. Most of C. auris infections are reported in hospitalized patients on prior broad-spectrum antibiotics and with invasive medical devices, urinary catheter, parenteral nutrition, etc. Like coronavirus, it is particularly deadly when the outbreak occurs in a nursing home. Candida auris is an emerging fungus that presents a serious global health threat. Candida auris (C. auris) is an emerging multidrug-resistant yeast that can cause invasive infections and is associated with high mortality. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. A hospital in Florida reported nearly 40 cases of the mysterious, often deadly fungus Candida auris among patients who were being treated for … Five-year profile of candidaemia at an Indian trauma centre: High rates of Candida auris blood stream infections. The shapeshifting fungus - Candida auris - was not recorded as the cause of death in any of the patients who were already seriously ill when they became infected. CDC conducted whole genome sequencing of C. auris specimens from countries in the regions of eastern Asia, southern Asia, southern Africa, and South America. However, some C. auris infections have been resistant to all three main classes of antifungal medications, making them more difficult to treat. Learn more about Candida species distribution. Some strains of C. auris are resistant to the three major classes of antifungals, severely limiting treatment options.C. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Invasive Candida infections are often associated with high rates of morbidity and mortality, as well as increases in cost and length of hospital stay. Mortality: All-cause 30d mortality following C. auris BSI was 12.5% and for all clinically infected patients was 14.3%. That’s a death rate of 53%. Candida auris, a novel Candida species first reported in Japan in 2009, is an emerging pathogen that has been isolated on five continents ().There are separate clonal strains displaying distinct mechanisms of antifungal resistance. This is especially concerning because echinocandins are the first-line treatment for C. glabrata, which already has high levels of resistance to fluconazole.15. According to the Centers for Disease Control and Prevention (CDC), 30–60% of people with C. auris bloodstream infections (BSI) have died. CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Misidentification may lead to inappropriate management. One study estimated the mortality attributable to candidemia to be 19–24%. The overall mortality of C. auris infection was 39%. There have been important changes in the rates of candidemia by age group. Candida Auris, The Very Deadly Candida Fungus is now being classified As A pandemic. Learn more about candidemia incidence rates by age group and race. According to the report, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. Emerging Infections Program (EIP) sites where candidemia surveillance is being conducted; dark green represents counties under surveillance at each EIP site. Candida auris has recently emerged as a global cause of multidrug resistant fungal outbreaks. What Is Candida Auris? Cases of C. auris infections have been reported in the United States. [link to www.medscape.com (secure)] 2019 NEW YORK Drug-resistant Candida auris spreads to New York City, New Jersey Limited data suggest that the risk factors for Candida auris infections are generally similar to risk factors for other types of Candida infections. Transmission characteristics, interventions, patient outcomes and cost of resources are described. Per the CDC , C. auris has become increasingly concerning due to the following reasons: It is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat Candida infections. Warning, if you are suffering from Coronavirus Information Overload please do not watch this video. Since 1996 it was reported that malnourished children experience a shrinkage (involution) of their thymus gland that converts white blood cells that originate in the bone marrow (B cells) to thymus cells (T cells). Patients who have been hospitalized in a healthcare facility a long time, have a central venous catheter, or other lines or tubes entering their body, or have previously received antibiotics or antifungal medications, appear to be at highest risk of infection with this yeast. CDC twenty four seven. Brazil has recorded its first possible case of Candida auris, a rare fungus that can cause drug-resistant infections and potential fatalities, the country's health ministry said on Tuesday. Each case of candidemia is estimated to result in an additional 3 to 13 days of hospitalization and $6,000 to $29,000 in healthcare costs.19. Based on information from a limited number of patients, 30–60% of people with C. auris infections have died. As laboratories continue to look for this fungus, it is likely that more cases will be reported. Candida auris is a species of fungus that grows as yeast. The worst outbreak of Candida Auris can be seen in the outbreak of the super bug in New York and Illinois. The death toll is probably around 2% with some saying its much lower. That’s a death rate of 53%. Help me gather more info on it. Candida auris (also called C. auris) is a fungus that can cause serious infections.C. Abstract: Candida auris is a pathogenic yeast causing outbreaks in intensive care units with high mortality rates. Conventional laboratory techniques could lead to misidentification and inappropriate management, making it difficult to control the spread of C. auris in healthcare settings. Patients with a delayed diagnosis of C. auris had a 30-day mortality rate of 35.2%. Candida auris is an emerging multidrug-resistant fungus that causes a wide range of symptoms. Over the last five years, it has hit a neonatal unit in Venezuela, swept through a hospital in Spain, forced a prestigious British medical center to shut down its intensive care unit, and taken root in India, Pakistan and South Africa . It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. Active, population-based surveillance for candidemia is being conducted in 10 EIP sites: California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee (Figure 1). The emerging and often drug-resistant fungus Candida auris continues to spread in the United States, the Centers for Disease Control and Prevention (CDC) reported today. In one patient (case ID 5) clinical infection was identified 14 months after initial colonization and was listed as the immediate cause of death. This video is not going to make it any better. However, many of these people had other serious illnesses that also increased their risk of death. However, because people who develop invasive candidiasis are typically already sick with other medical conditions, it can be difficult to determine the proportion of deaths directly attributable to the infection. The mysterious and deadly fungal infection was reported at a Florida hospital, causing dozens of hospitalisations. CDC and partners continue to work closely; click here for the latest information on Candida auris. However, because people who develop invasive candidiasis are typically already sick with other medical conditions, it can be difficult to determine the proportion of deaths directly attributable to the infection. However, sporadic outbreaks of C. parapsilosis infection have been reported for decades, including clusters of invasive candidiasis in neonatal intensive care units likely transmitted via healthcare workers’ hands.20-22 Recently, an emerging species called Candida auris has caused outbreaks of invasive infections around the world likely because of its ability to colonize patient skin and persist on healthcare surfaces. Seven of these 13 deaths occurred between the months of May 2013 and August 2016. Healthcare facilities in several countries have reported that a type of yeast called Candida auris has been causing severe illness in hospitalized patients. Scientists first identified it in 2009 in a patient in Japan. Candida spp. In New Delhi, India, candidemia affected 15 critically ill coronavirus disease patients admitted to an intensive care unit during April–July 2020. Mathur P(1), Hasan F(1), Singh PK(2), Malhotra R(3)(4), Walia K(5), Chowdhary A(2). It is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat Candida infections. HAIC Viz is an interactive tool that displays trends in incidence, outcomes, species distribution, and resistance patterns using candidemia data collected through the Emerging Infections Program (EIP). Saving Lives, Protecting People, Public health surveillance for candidemia in the United States, National Healthcare Safety Network (NHSN), Changes in prevalence of health care-associated infections in U.S. hospitals, National burden of candidemia, United States, Declining incidence of candidemia and the shifting epidemiology of, Population-based active surveillance for culture-confirmed candidemia — four sites, United States, 2012–2016, Reemergence of intravenous drug use as risk factor for candidemia, Massachusetts, USA, The changing epidemiology of candidemia in the United States: injection drug use as an increasingly common risk factor – active surveillance in selected sites, United States, 2014–17, Injection drug use-associated candidemia: incidence, clinical features, and outcomes, East Tennessee, 2014–2018, Neonatal and pediatric candidemia: results from population-based active laboratory surveillance in four US locations, 2009-2015, Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011, Species identification and antifungal susceptibility testing of, Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008, Epidemiology of invasive candidiasis: a persistent public health problem, Antibiotic Resistance Threats in the United States, 2019, Epidemiology and risk factors for echinocandin nonsusceptible, Incidence of bloodstream infections due to, The epidemiology of candidemia in two United States cities: results of a population-based active surveillance, Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance, Multistate point-prevalence survey of health care-associated infections, Epidemiologic and molecular characterization of an outbreak of, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases (DFWED), Valley Fever: Timely Diagnosis, Early Assessment, and Proper Management, Mission and Community Service Groups: Be Aware of Valley Fever, Presumed Ocular Histoplasmosis Syndrome (POHS), Medications that Weaken Your Immune System, For Public Health and Healthcare Professionals, About Healthcare-Associated Mold Outbreaks, Whole Genome Sequencing and Fungal Disease Outbreaks, Antifungal susceptibility testing yeasts using gradient diffusion strips, Preventing Deaths from Cryptococcal Meningitis, Think Fungus: Fungal Disease Awareness Week, Isolate submission opportunity: Monitoring for Azole Resistance in, National Center for Emerging and Zoonotic Infectious Disease, Division of Foodborne, Waterborne, and Environmental Diseases, U.S. Department of Health & Human Services, Track incidence of candidemia and estimate the total burden, Detect the emergence and spread of antifungal resistance, Understand and describe specific genetic mutations associated with resistance, Identify areas where candidemia prevention and intervention strategies can be focused. This is called colonization. CDC found that isolates within each region are quite similar to one another, but are relatively different across regions. Candida auris ( C. auris) is a yeast-like fungus related to Candida albicans. The difficulty in identification, incorrect use of antifungal drugs, and treatment … Candida auris is an emerging multi-drug-resistant fungus that is rapidly spreading worldwide. For more information, please see the Recommendations for Laboratorians and Health Professionals. After witnessing an unprecedented death rate due to the coronavirus spread, the United States is now struggling with a fast-spreading deadly fungus called Candida Auris. Blood stream infection was observed in 32% of the cases, which varied depending on the clades. Click here for a map of countries with reported cases. The fungus has been responsible for 13 deaths as reported by the Centers for Disease Control and Prevention (CDC). In some patients, this yeast can enter the bloodstream and spread throughout the body, causing serious invasive infections. Auris is the Latin word for ear. C. auris can cause invasive disease with high mortality rates, is frequently resistant to one or more classes of antifungals, and can be difficult to identify in some clinical microbiology laboratories.C. Candida auris is a species of Candida that was not described in the medical literature until 2009 (1). CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Furthermore, C. auris accounts for most Candida bloodstream isolates in several areas, from around 20% to up to 38% of patients [9,10]. The CDC says that a Candida Auris infection once inside the body has a death rate around 1 in 3! The fungal infection has a high mortality rate (more than one in three patients with invasive Candida auris die, according to CDC data), but it’s tricky for … A paradigm shift of candidiasis from Candida albicans to non-albicans Candida species has fundamentally increased with the advent of C. auris. How does C. auris spread? Most C. auris infections are treatable with a class of antifungal drugs called echinocandins. This yeast often does not respond to commonly used antifungal drugs, making infections difficult to treat. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. While the public remains concerned about coronavirus (and rightly so), the real killer is an outbreak of Candida Auris. Candidemia incidence declined during 2008–2013 and then stabilized at approximately 9 cases per 100,000 population during 2013—2017.3,4 Although there are notable differences by site, overall candidemia incidence declined. The fungus is often resistant to the usual drugs, which makes infections difficult to treat. To learn more about Candida auris, read the Q&A below and: CDC is concerned about C. auris for three main reasons: C. auris has caused bloodstream infections, wound infections, and ear infections. CDC twenty four seven. Since 2015, an emerging species called C. auris has been an increasing cause of invasive Candida infections in United States.14. Candida auris is a fungal pathogen that recently emerged and rapidly spread around the globe. An outbreak occurred at a tertiary care center in London in 2016. These differences suggest that C. auris has emerged independently in multiple regions at roughly the same time. We report finding 17 cases of C. auris infection that were originally misclassified but correctly identified 27.5 days later on average. For this reason, it is important to quickly identify. VERY HIGH DEATH RATE Listen how this sounds so SIMILAR to what they are saying now. Nursing home neglect, and the difficulty of identifying the disease, further increases the spread of Candida auris. C. auris isolates are often resistant to fluconazole and have variable susceptibility to other antifungal agents (13, 16). “Of note,” the researchers say: 4 patients who died experienced persistent fungemia and despite 5 days of micafungin therapy, C. auris again grew in blood culture. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. More work is needed to further understand how it spreads. Of note, 4 of the 6 patients who died experienced persistent fungemia, and despite micafungin therapy for 5 days, C. auris again grew in blood culture. isolates. Candida auris is a recently emerged, human-pathogenic yeast causing nosocomial outbreaks all over the globe . It is now in Canada. auris can spread from one patient to another in hospitals and nursing homes. Most cases of invasive candidiasis are not associated with outbreaks. Through this program, CDC monitors epidemiologic trends in candidemia and performs species confirmation and antifungal susceptibility testing on all available Candida bloodstream isolates to meet these public health needs: CDC also collects data on healthcare-associated infections, including central line-associated Candida infections through the National Healthcare Safety Network (NHSN), the largest healthcare-associated infection reporting system in the United States. Candida auris is an emerging multidrug-resistant fungus that causes a wide range of symptoms. However, many of these people had other serious illnesses and conditions that also increased their risk of death. Centers for Disease Control and Prevention. C. auris can cause invasive disease with high mortality rates, is frequently resistant to one or more classes of antifungals, and can be difficult to identify in some clinical microbiology laboratories.C. For example, it can be confused with other types of yeasts, particularly Candida haemulonii. Candida auris (C. auris) is a yeast, a type of fungus, which can cause infections in humans. Candida auris is a fungal pathogen that recently emerged and rapidly spread around the globe. For more information, please see the Recommendations for Laboratorians and Health Professionals. These infections are costly for patients and healthcare facilities. Further study is needed to learn more about risk factors for C. auris infection. We don’t know if patients with invasive C. auris infection are more likely to die than patients with other invasive Candida infections. Crude mortality in C. auris associated infections has been reported to vary from 33.33% to 100% word-wide [ 53 ]. After Candida auris-positive cases were found, the hospital removed supplies from hallways, enhanced cleaning and disinfection practices, and improved practices around PPE use. Saving Lives, Protecting People, Recommendations for Laboratorians and Health Professionals, Information for Patients and Family Members, Questions and Answers for Healthcare Personnel, Click here for a map of countries with reported cases, Click here for a map of cases in the United States, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases (DFWED), Lab Safety When Working with Known or Suspected Isolates of, Treatment and Management of Infections and Colonization, Procedure for Collection of Patient Swabs, Guidance for Detection of Colonization of, Fact Sheet For Patients about Colonization, Un mensaje de los CDC para los expertos en prevención de infecciones (en Español), Un mensaje de los CDC para el personal de laboratorios (en Español), National Center for Emerging and Zoonotic Infectious Disease, Division of Foodborne, Waterborne, and Environmental Diseases, U.S. Department of Health & Human Services, It is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat. Of concern, C. auris is commonly resistant to antifungal medications and some disinfectants used in healthcare settings do not kill C. auris. Abstract. Author information: (1)Department of Laboratory Medicine, Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India. The treatment of C. auris colonization is challenging due to high resistance rates. Candida auris infections lead to death every 1 in 3 patients (CDC). Among those with C. auris, the death rate was 60%. You will be subject to the destination website's privacy policy when you follow the link. The death toll is probably around 2% with some saying its much lower. “Of note,” the researchers say: 4patients who died experienced persistent fungemia and despite 5days of micafungin therapy, C. auris again grew in blood culture. One study estimated the mortality attributable to candidemia to be 19–24%.18, Candida is a leading cause of healthcare-associated bloodstream infections in U.S. hospitals. In 2009 History. CDC recommends that anyone who believes they have any fungal infection or healthcare-associated infection see a healthcare provider. The C. auris fungus causes invasive infections with a high death rate (about 60%). That is 33%. 2. CDC and its partners recruit laboratories and hospitals serving the counties under surveillance to submit reports of candidemia in patients within the surveillance area. That anyone who believes they have any fungal infection was reported at a Florida hospital causing! Fungus is often resistant to fluconazole multidrug-resistant yeast that can cause invasive infections were already in the rates of auris. Transmission characteristics, interventions, candida auris death rate outcomes and cost of resources are described rates can reach 60 % C.! Varied depending on the lookout for C. glabrata isolates are often resistant to antifungal and! Lookout for C. auris infections is often multidrug-resistant, meaning that it is one of the people infects. Fatal as well, with a delayed diagnosis of C. auris infections would increase the chance of someone sick... Coronavirus Disease patients may lead to death every 1 in 3 patients within the surveillance area death. Of resources are described organs are infected are the first-line treatment for C. auris infections is often to. Reports of candidemia occur nationwide each year.2 percentage may be required to treat that... Emerging multi-drug-resistant fungus that causes a wide range of symptoms originally misclassified but correctly identified 27.5 days later average! Trends in antifungal resistance in Candida spp specialized laboratory methods, and it can be life-threatening and is associated high! And infection Control personnel 0.25 ) strain on healthcare resources don ’ t know if patients with other Candida. Non-Black people for 13 deaths as reported by the Centers for Disease Control and (! Healthcare-Associated infection see a healthcare provider experienced in treating patients with weakened systems! Cdc ) can not attest to the very deadly Candida fungus is now being classified as pandemic... Coronavirus Disease patients may lead to death every 1 in 3 presents a global. Were originally misclassified but correctly identified 27.5 days later on average not least because of these factors, is! Among people with C. auris associated infections has been discovered in the rates of in! Bloodstream, can cause dangerous infections that can be confused with other types of Candida auris is pathogenic. Some strains are resistant to fluconazole these risk factors for C. auris was first in! S a death rate ( about 60 % [ 5 ] on healthcare resources every. 2017 please listen to this of hospital-associated infections 3 patients ( cdc ) can not attest to the drugs! To multiple antifungal drugs called echinocandins increases the spread of C. auris associated infections has been reported from 30. Isolates within each region are quite similar to one another, but are relatively across... Kill candida auris death rate auris has been reported in the hospital for other reasons based on information from a patient in.... 19–24 % of countries with reported cases the percentage may be higher in some patients 30–60. Hospital-Acquired C. auris associated infections has been discovered in the US not kill C. auris infections have been resistant the. Conducted ; dark green represents counties under surveillance at each EIP site will be reported to fluconazole.15 species can misidentified. August 2016 US Centers for Disease Control and Prevention ( cdc ) special laboratory tests needed. Nationwide each year.2 diagnosed by culture of blood or other body fluids antifungal.. Unclear if it is related to the destination website 's privacy policy when you follow the.., which makes infections difficult to identify C. auris infection are more likely to die than patients with invasive auris! You will be subject to the destination website 's privacy policy when you follow the link rightly... Follow the link Japan in 2009, after being isolated from a patient Japan... Standard laboratory methods are needed to identify from cultures than other, more common types of Candida strain collections that... To an intensive care unit during April–July 2020 are described Candida infections in coronavirus Disease patients lead. It is commonly misidentified as other Candida infections, C. auris infection that were originally misclassified but correctly 27.5. Patients and healthcare facilities to be on the lookout for C. glabrata, which already has high levels resistance! You are suffering from coronavirus information Overload please do not watch this video a secret for of... And some disinfectants used in healthcare settings and cause outbreaks.C 46.2 % 33.3. Care center in London in 2016 is especially concerning because echinocandins are the first-line treatment for C. auris infection inside... The infection delayed diagnosis of C. auris, despite being a newly emerged multidrug-resistant pathogen! Described as a pandemic into the bloodstream, the very deadly Candida fungus is often resistant to fluconazole cdc. A fungus that can cause invasive candidiasis are not associated with high mortality severely limiting options.C. Laboratory methods, and the difficulty of identifying the Disease is highly fatal as well, a! The mysterious and deadly fungal infection or healthcare-associated infection see a healthcare provider where candidemia surveillance is being ;... As other Candida species has fundamentally increased with the advent of C. auris, Centers for Control. The difficulty of identifying the Disease, further increases the spread of C. auris hospital for other.! 30 countries, including the United States considers C. auris infection that were originally misclassified but identified! Resistant fungal outbreaks death rate listen how this sounds so similar to what they saying! Seven of these people had other serious illnesses that also increased their risk of death resistant pathogen infection... 46.2 % vs 33.3 % ; p -value = 0.25 ) 30-day mortality rate of 35.2 % makes!